Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval
The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical...
Sino Biopharmaceutical Terminates IPO Pre-Listing Process for STAR Board
Sino Biopharmaceutical Ltd (HKG: 1177) has announced the decision to terminate the pre-listing process for...
Shanghai Pinnacles Partners with Sysmex for Biochemical Immune Diagnosis Solutions
China’s Shanghai Pinnacles Medical Technology Co., Ltd has struck a partnership with Japan-based Sysmex Corporation,...
GenScript ProBio Partners with Bio Immunitas for hRPP Platform
Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a...
ImmVira’s MVR-T3011 IT Shows Efficacy in Melanoma Treatment
Shenzhen-based biopharma ImmVira has revealed that its first intra-tumoral injection oncolytic virus (OV) product, MVR-T3011...
Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs
China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and...
Neurodawn Completes Series A+ Financing for CNS Drug Development
Neurodawn Pharmaceutical Co., Ltd, a central nervous system (CNS) drug developer based in Nanjing, has...
Grand Pharma Completes Patient Enrollment for STC3141 Sepsis Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that all patients have completed enrollment...
Eyebright Medical Gains SIX Swiss Exchange Approval for GDR Offering
Beijing-based ophthalmic device maker Eyebright Medical Technology Co., Ltd (SHA: 688050) has announced receiving conditional...
Teddy Clinical Research Lab Partners with Cerba Research for Global Services
China-based Teddy Clinical Research Laboratory Limited, a joint venture (JV) between Dian Diagnostics (SHE: 300244)...
Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma
Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply...
Macrolux Secures Series A Funding for Endoscopy Solutions
Macrolux, an endoscopy intervention solutions provider based in Shenzhen, has reportedly raised close to RMB...
Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin
China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...
SciClone Pharmaceuticals Files for Hong Kong Market Approval of Danyelza
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...
Asia Regenerative Medicine Raises Pre-Series A+ Funding for Bioartificial Organs
Shenzhen-based Asia Regenerative Medicine (ARM) has reportedly raised “tens of millions” of renminbi in a...
Beijing Smart Beam Raises Series A+ Funding for CT X-Ray Tube Development
Beijing Smart Beam Technology, a leading vacuum electronic device maker, has reportedly raised “tens of...
Asieris Partners with ReviR Therapeutics for Urogenital Cancer Research
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has struck a...
Siemens Healthineers Reports Q1 Revenue Drop Amid COVID-19 Impact
Germany-based medical device giant Siemens Healthineers AG has released its fiscal year 2023 Q1 financial...
Astellas Pharma Reports Strong Q3 Results with 17.3% Revenue Growth
Japan-based Astellas Pharma Inc. (TYO: 4503) has released its financial report for Q3 of its...
Fujian Cosunter’s HBV Therapy GST-HG141 Begins Phase II Trial
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the first patient enrollment and...